An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Apr 2018
Price : $35 *
At a glance
- Drugs Migalastat (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Registrational
- Sponsors Amicus Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 27 Apr 2018 This trial has been completed in Spain.
- 12 Jan 2018 This trial was completed in Austria, according to European Clinical Trials Database.